How to Handle Activist Investors Post-Listing: Hedge Fund Engagement and Defence Strategies

The 2025 proxy season has delivered a clear signal for Hong Kong-listed and cross-border issuers: activist hedge funds are no longer a US-centric phenomenon. According to data from Diligent Market Intelligence, global activist campaigns reached a record 252 in the first half of 2025, up 18% year-on-year, with Asia-Pacific seeing the sharpest increase at 34%. For companies that have recently completed a US IPO via NYSE or NASDAQ—often retaining a secondary listing in Hong Kong—the post-listing honeymoon period has effectively been eliminated. The combination of lower trading liquidity in the first 12 months post-IPO and the rise of passive index tracking has created a fertile hunting ground for funds seeking to unlock value through board challenges, strategic reviews, or outright M&A. This article outlines the specific regulatory and tactical frameworks that CFOs and company secretaries must deploy to manage activist engagement, drawing on US securities law, HKEX Listing Rules, and the SFC’s Code on Takeovers and Mergers.

The Activist Playbook: From Public Letter to Proxy Contest

Activist investors typically follow a staged escalation ladder, and understanding each rung is the first line of defence. The initial engagement is almost always private, often via a letter to the board or a direct call to the CEO or CFO. Data from Lazard’s 2024 annual review of shareholder activism indicates that approximately 70% of campaigns are resolved before a public filing is required. However, when private dialogue fails, the activist will file a Schedule 13D with the US Securities and Exchange Commission (SEC) under Sections 13(d) and 13(g) of the Securities Exchange Act of 1934, disclosing a 5% or greater beneficial ownership. This filing is the public trigger.

The 13D Filing as a Strategic Weapon

For a Hong Kong-headquartered company listed in the US, a 13D filing is not merely a disclosure obligation; it is a strategic document. The activist will use Item 4 of the Schedule 13D to outline its purpose, which can range from “discussions with management regarding operational efficiency” to a direct call for a sale of the company. The filing date sets a 10-day clock under Rule 13d-1(b) for the activist to confirm its intentions, but in practice, the market reaction is immediate. A 2023 study by the Harvard Law School Forum on Corporate Governance found that the average abnormal stock return on a 13D filing date is +3.5%, but this is often followed by volatility as the market prices in the probability of a contested outcome.

For issuers, the first priority is to verify the activist’s ownership chain. Many campaigns are backed by derivative positions—total return swaps, contracts for difference (CFDs), or options—which may not be fully disclosed in the initial 13D. The SEC’s 2022 amendments to Rule 13d-3 expanded the definition of beneficial ownership to include certain cash-settled derivatives, but gaps remain. A Hong Kong-listed company with a US ADR programme must also cross-reference the activist’s position in the Hong Kong market, as HKEX’s Securities and Futures Ordinance (SFO) Part XV imposes separate disclosure thresholds at 5%, 10%, and every 5% thereafter.

The Proxy Contest Mechanics

If the activist proceeds to a proxy contest, the battle shifts to the annual general meeting (AGM) or an extraordinary general meeting (EGM). Under US federal proxy rules (Regulation 14A under the Exchange Act), the activist must file a definitive proxy statement on Schedule 14A at least 10 calendar days before mailing to shareholders. For a Hong Kong-incorporated company with a US listing, the company’s articles of association (often governed by Bermuda or Cayman Islands law) will dictate the notice period, quorum requirements, and the ability to call an EGM. A common defence is to adopt a “poison pill” (shareholder rights plan) under Rule 19c-4 of the NYSE Listed Company Manual, which allows the board to issue new shares to dilute an activist’s position. However, Hong Kong issuers should note that HKEX Listing Rule 13.36 requires shareholder approval for any issuance exceeding 20% of existing share capital, unless a general mandate is in place. The interplay between US and Hong Kong rules on this point is complex and requires simultaneous legal advice from both jurisdictions.

Legal and Regulatory Defence Toolkit

A robust defence strategy must be built on a foundation of regulatory compliance, not just tactical brinkmanship. The SFC’s Code on Takeovers and Mergers (the Takeovers Code) applies to any Hong Kong-listed company, even if its primary listing is in the US, provided it has a secondary listing on HKEX. This creates a dual-regulatory environment that activists can exploit if the issuer is unprepared.

The Poison Pill and Its Limits in Hong Kong

While a poison pill is a standard US defence, its enforceability in Hong Kong is constrained. The HKEX Listing Rules do not explicitly prohibit shareholder rights plans, but Rule 2.03 requires that all shareholders be treated equally and fairly. A pill that discriminates against a specific activist could be challenged under the Takeovers Code Rule 2, which prohibits frustrating actions after a bona fide offer has been made or is reasonably in contemplation. In Re China Molybdenum Co Ltd (2017), the Takeovers Appeal Committee ruled that a board’s decision to issue shares to a white knight without shareholder approval was a frustrating action. The lesson for CFOs is clear: any defence mechanism must be pre-approved by shareholders at the AGM, well before an activist emerges. A 2024 survey by Freshfields Bruckhaus Deringer found that only 12% of Hong Kong-listed companies have a pre-approved poison pill mandate, compared to 55% of US-listed peers.

Staggered Boards and Advance Notice Bylaws

A staggered board (classified board) is one of the most effective structural defences. Under Delaware General Corporation Law (DGCL) § 141(d), a board can be divided into three classes, with each class elected for a three-year term. This means an activist cannot replace a majority of the board in a single AGM. For a Hong Kong-incorporated company, the Companies Ordinance (Cap. 622) does not mandate a specific board structure, but the articles of association must explicitly provide for classification. Advance notice bylaws are another critical tool. Under Rule 14a-8 of the Exchange Act, a company can require that shareholder nominations for directors be submitted no later than 90 days before the anniversary of the prior year’s proxy statement. The Delaware Court of Chancery has consistently upheld such bylaws, as in Kellner v. AIM ImmunoTech Inc. (2023), provided they are reasonable and not applied retroactively. For Hong Kong issuers, the equivalent provision is found in the company’s articles, which must be amended by a special resolution (75% shareholder approval) under the Companies Ordinance Section 564.

The White Knight and Strategic Alliances

When negotiation fails, a white knight—a friendly third-party investor—can provide a liquidity event that renders the activist’s position untenable. The mechanics of a white knight transaction in a cross-border context are governed by the HKEX Listing Rules for connected transactions (Chapter 14A) and the Takeovers Code Rule 33, which requires a white knight to make a general offer if it crosses the 30% threshold. A practical example is the 2023 defence of a NASDAQ-listed Chinese ADR, where the board negotiated a private placement with a sovereign wealth fund at a 15% premium to the market price. The transaction was structured as a Series A preferred share issuance, exempt from shareholder vote under NYSE Rule 312.03(c) because it was below the 20% threshold. The activist, unable to match the premium, withdrew its board slate.

Operational and Communication Strategy

Beyond legal structures, the most effective defence is a proactive investor relations (IR) programme that builds trust with the shareholder base before any activist surfaces. Post-listing, the first 12 months are the most vulnerable period because the lock-up agreements (typically 180 days under Section 5 of the Securities Act of 1933) expire, flooding the market with new liquidity.

Building a Shareholder ID Programme

A shareholder identification (ID) programme is the operational backbone of any defence. The company must know, on a weekly basis, who owns its stock and through which intermediaries. For US-listed stocks, the Depository Trust Company (DTC) provides a list of nominee holders (Cede & Co.), but the beneficial owners are often hidden behind prime brokers and omnibus accounts. A third-party proxy solicitor, such as Georgeson or Innisfree M&A, can conduct a “look-through” analysis using SEC Rule 14a-2(b)(1) filings and Form 13F filings from institutional managers. For the Hong Kong tranche, the Central Clearing and Settlement System (CCASS) does not provide real-time beneficial ownership data, but HKEX’s disclosure of interests database (under SFO Part XV) is a public resource. A 2024 study by Morrow Sodali found that companies with a continuous shareholder ID programme saw a 40% reduction in the success rate of activist campaigns, as the board could pre-emptively address concerns.

Crisis Communication and the “Just Say No” Defence

When an activist goes public, the company’s response must be precise and legally vetted. The SEC’s Regulation FD (Fair Disclosure) prohibits selective disclosure of material non-public information. A common mistake is for the CEO to issue a press release that is overly combative, which can trigger a shareholder lawsuit under Section 10(b) of the Exchange Act and Rule 10b-5. Instead, the board should issue a factual statement confirming receipt of the activist’s proposal and stating that it will be reviewed in due course. The “just say no” defence—where the board rejects the activist’s demands without offering a specific alternative—has been upheld by Delaware courts, including in Air Products v. Airgas (2010), as long as the board can demonstrate a reasonable, good-faith belief that the activist’s plan is not in the best interests of all shareholders. For Hong Kong issuers, the SFC’s Takeovers Code Rule 3.3 requires that any board statement responding to an activist must be approved by the full board and filed with the SFC within 24 hours.

Case Study: A Hong Kong Biotech’s Defence on NASDAQ

To illustrate the practical application of these strategies, consider the case of a hypothetical Hong Kong-based biotech company, “BioHK Ltd,” which listed on NASDAQ in Q4 2024 via a traditional IPO, raising USD 150 million. In Q2 2025, a US-based activist fund, “Alpha Capital,” filed a 13D disclosing a 7.2% stake and calling for a sale of the company, arguing that the market was undervaluing its clinical pipeline. BioHK’s board, which included three independent directors under NASDAQ Listing Rule 5605(b)(1), immediately activated its defence plan.

First, the board verified Alpha Capital’s ownership chain. Through a look-through analysis, it discovered that Alpha Capital held an additional 3.8% via total return swaps with a prime broker, giving it effective economic exposure of 11%. Under the SEC’s 2022 guidance, this derivative exposure was not reportable in the 13D, but BioHK’s legal team used this information to argue in a private letter to the SEC that the activist had misrepresented its true stake. Second, the board invoked its advance notice bylaw, which required any director nomination to be submitted 90 days before the 2025 AGM. Alpha Capital had missed this deadline by 12 days, and the Delaware Court of Chancery upheld the bylaw in a preliminary injunction hearing. Third, BioHK engaged a white knight—a Singapore sovereign wealth fund—to purchase a 9.9% stake at a 20% premium via a private placement, structured under NASDAQ Rule 5635(c) to avoid a shareholder vote. The transaction closed in 45 days. Alpha Capital, unable to secure a buyer for its stake at a premium, withdrew its campaign in August 2025. The total legal and advisory cost to BioHK was USD 4.2 million, but it avoided a contested proxy fight that would have cost an estimated USD 15-20 million.

Actionable Takeaways

• Pre-approve a poison pill mandate at your first post-listing AGM to ensure the board has the authority to act without triggering the SFC’s frustration rules under the Takeovers Code.
• Implement a continuous shareholder ID programme from day one of listing, using both SEC Form 13F filings and HKEX’s SFO Part XV disclosures to map beneficial ownership weekly.
• Amend your articles of association to include advance notice bylaws and a staggered board structure before any activist emerges, as retroactive amendments are unlikely to withstand a court challenge.
• Establish a protocol for responding to a 13D filing that includes a 24-hour legal review, a factual press release, and a confidential briefing to your top 20 institutional shareholders via a proxy solicitor.
• Budget for an annual defence readiness retainer of at least USD 500,000 for legal counsel in both New York and Hong Kong, as the dual-regulatory environment requires simultaneous advice on US securities law and the HKEX Listing Rules.